Koronis Pharma Inc is categorized under Noncommercial Biotechnical Research in Seattle, WA and active since 1997.
Koronis Pharma Inc was established in 1997, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Noncommercial Biotechnical Research business, which does work in the B2B market, and is classified as a Noncommercial Biotechnical Research, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Donald Elmer at the company’s single location by writing to 800 5th Avenue # 4120, Seattle, Washington WA 98101 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Koronis Pharma Inc |
| Contact Person: | Donald Elmer |
| Address: | 800 5th Avenue # 4120, Seattle, Washington 98101 |
| Website Address: | koronispharma.com |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 1997 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Noncommercial Biotechnical Research |
| SIC Code: | 8733 |
| NAICS Code: | 541720 |
| Share This Business: |
Koronis Pharma Inc was started in 1997 to provide professional Noncommercial Biotechnical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Donald Elmer for inquiries that concern Koronis Pharma Inc by calling the company number No number given, as your correspondence is most welcome. Additionally, the physical location of the single location of Koronis Pharma Inc can be found at the coordinates 47.605378,-122.330493 as well as the street address 800 5th Avenue # 4120 in Seattle, Washington 98101.
For its online presence, you may visit Koronis Pharma Inc’s website at koronispharma.com and engage with its social media outlets through on Twitter and on Facebook.